Qinglong Guo
13PUBLICATIONS
27CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (13)
Sort by Publication Date:
|Mar 27, 2025
Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma.Shuaishuai Xing, Jiheng Jiang, Xianglin Chu
|Jul 06, 2023
Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.Siyu He, Xianglin Chu, Yujia Wu
|Mar 24, 2023
Targeting lysosomal HSP70 induces acid sphingomyelinase-mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies.Yingjie Qing, Yongjian Guo, Qinwen Zhao
|Aug 18, 2022
Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance.Siyu He, Yang Liu, Xianglin Chu
|Jun 30, 2022
AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma.Di Pan, Wanwan Yang, Yao Zeng
|Oct 04, 2021
One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence.Yingjie Qing, Hui Li, Yunzi Zhao
Pageof 3
